Predict your next investment


See what CB Insights has to offer


Acquired | Acquired

Total Raised


About Forcare

Forcare is a software company providing software products and services for healthcare. The company's focus is "interoperability" between healthcare IT systems, providing products and services to allow existing systems to (electronically) interconnect to share and exchange patient data. Based on its solution, a comprehensive and complete view of available patient information is realized.

Forcare Headquarter Location

Laan van Vollenhove 2931

Zeist, 3706 AK,


+31 30 699 1930

Latest Forcare News

Provident Healthcare Partners Advises ForCare Clinical Research In Its Partnership With CenExcel Clinical Research

Aug 12, 2021

News provided by Share this article Share this article BOSTON and LOS ANGELES, Aug. 12, 2021 /PRNewswire/ -- Provident Healthcare Partners (Provident), a leading healthcare investment banking firm, announced that it has advised ForCare Clinical Research (FCR, ForCare CenExcel FCR, or the Company) in its partnership with CenExel Clinical Research, a portfolio company of Webster Equity Partners. FCR is a leading independent dermatology focused clinical research site conducting Phase II, III and late Phase I studies in both chronic and acute conditions on behalf of pharma and biotech sponsors, with additional exposure to rheumatology, neurology, immunology, inflammatory disease, and internal medicine. By acquiring Tampa-based FCR, CenExel dramatically strengthens its ability to support clinical research in dermatology and immunology, as well as several other therapeutic areas. FCR's Principal Investigators have over 40 years of combined research experience in the execution of Phase I through Phase IV clinical trials. "The many strengths at CenExel FCR align perfectly with CenExel's mission to be the leader in therapeutically focused clinical research. With this addition, CenExel now has the leading platform to conduct clinical trials in Dermatology, CNS, Vaccine, and Clinical Pharmacology," said Tom Wardle, CenExel CEO. "This addition elevates our entire network. I look forward to working alongside the amazing team at CenExel FCR as we continue to grow together." "CenExel FCR will keep exceeding enrollment expectations, preserving subject retention, reducing trial timelines, and delivering reproducible, quality data," said Misty Sturges, Chief Operating Officer at CenExel FCR. "We're excited to see even faster study start-up and efficiencies by employing CenExel's site network resources in our single- and multi-site studies." "FCR's deep understanding of the dermatology and inflammatory disease therapeutic landscape, and it's proven commitment to operational excellence in conducing trials with the greatest efficiency and highest quality metrics, has allowed the Company to increase active trial protocols substantially quarter-to-quarter over the past several years including clinical research on behalf of nearly all the leading dermatologic and inflammatory disease focused sponsors in the pharmaceutical industry," noted Ethan Goodson , Director at Provident. CenExel Clinical Research, Inc. was formed in 2018, and since its formation, CenExel has energetically pursued organic growth as well as the acquisitions of state-of-the-art research centers around the U.S. The mission of CenExel is to work with trial Sponsors and Contract Research Organizations to reduce costs and development times for innovative therapies which may advance patient care. About CenExel Clinical Research CenExel Clinical Research ( ) provides unparalleled medical and scientific support in the design and execution of clinical trials. CenExel's therapeutic area focus and attention to detail assures quality, reliable results and has helped CenExel to consistently achieve and exceed patient recruitment goals. CenExel Centers of Excellence have conducted thousands of studies, the variety and complexity of which have resulted in a vast depth of experience and insight for the Principal Investigators and research staff in each facility. The CenExel Centers of Excellence deliver the engagement, expertise, and results to ensure that their clients achieve their clinical research goals. About Provident Healthcare Partners Provident is a leading healthcare investment banking firm specializing in merger and acquisition advisory, strategic planning, and capital formation for healthcare companies. The firm has a comprehensive knowledge of market sectors and specialties, including a significant track record of success within pharma services. Provident also has unsurpassed experience and insight into the M&A process, which includes working with a number of buyers such as private equity firms and strategic consolidators. For additional information, visit or follow on LinkedIn . Contact:

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Forcare

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Forcare is included in 2 Expert Collections, including Digital Health.


Digital Health

12,256 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)


Health IT

1,849 items

This collection includes public and private companies, as well as startups, that market software solutions to healthcare provider organizations.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.